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Abstract
Purpose: Pazopanib is a potent, multitargeted receptor tyrosine kinase inhibitor; however, there is
limited information regarding the effects of liver function onpazopanibmetabolism andpharmacokinetics.
The objective of this study was to establish the maximum-tolerated dose (MTD) and pharmacokinetic
profile of pazopanib in patients with varying degrees of hepatic dysfunction.
Experimental Design: Patients with any solid tumors or lymphoma were stratified into four groups
based on the degree of hepatic dysfunction according to the National Cancer Institute Organ Dysfunction
WorkingGroup (NCI-ODWG) criteria. Pazopanibwas given orally once a day on a 21-day cycle. Amodified
3þ3 design was used.
Results: Ninety-eight patients were enrolled. Patients in the mild group tolerated 800 mg per day.
The moderate and severe groups tolerated 200 mg per day. Pharmacokinetic data in the mild group were
similar to the data in the normal group. Comparison of the median Cmax and area under the curve
[AUC(0–24)] in the moderate or severe groups at 200 mg per day to the values in the normal and mild
groups at 800 mg per day indicated less than dose–proportional systemic exposures in patients with
moderate and severe hepatic impairment. This suggests that the lower maximum-tolerated dose in the
moderate and severe group is not due to a decrease in drug clearance or alteration in the proportion of
metabolites.
Conclusions: In patients with mild liver dysfunction, pazopanib is well tolerated at the Food and Drug
Administration (FDA)–approved dose of 800 mg per day. Patients with moderate and severe liver
dysfunction tolerated 200 mg per day. Clin Cancer Res; 19(13); 3631–9. 2013 AACR.
Introduction
Pazopanib is a potent, multitargeted receptor tyrosine
kinase inhibitor approved for the treatment of renal cancer
(1). Pazopanib inhibits angiogenesis and lymphangiogen-
esis by targetingmultiple receptors including VEGF receptor
(VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth
factor receptor (PDGFR)-a, PDGFR-b, and c-kit (2). The
primary route of metabolism is hepatic, but there is limited
information regarding the effects of liver function on pazo-
panib metabolism and pharmacokinetics (3).
In the initial phase I clinical trial of pazopanib in patients
with advanced cancer, a total of 63 patients were treated at
varying dose escalation cohorts ranging from 50mg 3 times
per week to 2,000 mg once daily and 300 to 400 mg twice
daily. Patients with aspartate aminotransferase (AST) or
alanine aminotransferase (ALT)more than2 times the upper
limit of normal (ULN) were excluded from that trial. The
most common adverse events were hypertension, diarrhea,
hair depigmentation, and nausea. Dose-limiting toxicities
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observed at the 50, 800, and 2,000 mg dose levels included
gastrointestinal hemorrhage, extrapyramidal involuntary
movements, and fatigue. Hypertension was the most com-
mon grade 3 toxicity. Abnormal liver function tests with
elevated aspartate aminotransferase (AST), alanine amino-
transferase (ALT), andbilirubinwere observed in 38%,24%,
and 13% of patients, respectively (3). In another phase I
study conducted in patients with hepatocellular carcinoma,
subjects with serum bilirubin less than 2.0 mg/dL (Child-
Pugh A) were eligible. The maximum-tolerated dose was
determined to be 600 mg per day, and the dose-limiting
toxicities were grade 3 AST/ALT elevations and malaise (4).
In subsequent clinical trials using pazopanib, hepatotoxicity
with ALTmore than 3 times theULNwas reported in 14%of
patients andALTmore than 8 times theULNwas reported in
4% of patients. These studies suggest that pazopanib dosage
has yet to be optimized and may affect patients differently
based on their degree of clinical hepatic dysfunction (5).
Fourpazopanibmetabolites (GSK1268992,GSK1268997,
GSK1071306, and GW700201) have been identified. Only
one of these metabolites (GSK1268997) has been shown to
inhibit the proliferation of VEGF-stimulated human umbil-
ical vein endothelial cells with potency similar to pazopanib.
Theothermetabolites showat least 10- to 20-fold less activity
than the parent compound in the same cellular assay. The
oxidativemetabolismof pazopanib ismediated primarily by
CYP3A4, with minor contributions from CYP1A2 and
CYP2C8 (6). In vitro studies also indicate that pazopanib is
a potential inhibitor ofCYP2C9,CYP1A2,CYP2A6,CYP2B6,
CYP2C8, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (data
on file; GlaxoSmithKline). In patients with cancer, pazopa-
nib was a weak inhibitor of CYP3A and CYP2D6 isozymes
and had no effect on the pharmacokinetics of probe sub-
strates for CYP1A2, CYP2C9, or CYP2C19 (7). Therefore,
clinical liver function may affect pazopanib pharmacokinet-
ics and its subsequent pharmacodynamics. In patients with
normal liver function, previous pharmacokinetic studies
showed similar area under the curve (AUC0–24), Cmax, and
C24 values after daily administration of doses from 800 to
2,000 mg per day. This suggested that doses above 800 mg
per day would not increase activity and 800 mg per day was
the recommended dose for future studies. Currently, there is
limited information regarding the effects of liver function on
pazopanib metabolism and pharmacokinetics. This study
wasdesigned toestablish themaximum-tolerateddose, dose-
limiting toxicities, and pharmacokinetics profile of pazopa-
nib in patients with varying degrees of hepatic dysfunction.
Patients and Methods
Eligibility criteria
Eligible patients were 18 years or more of age with a life
expectancy of more than 3 months and a Karnofsky Per-
formance Status of 60%ormore. All patientsmust have had
a histologically or cytologically confirmed solid tumor or
lymphoma except patients with hepatocellular carcinoma
diagnosed by an elevateda-fetoprotein level (500 ng/mL)
and positive serology for hepatitis. Other eligibility
criteria included: absolute neutrophil count (ANC) of 
1.5109/L, platelets100109/L; serumcreatinineULN;
or a calculated ormeasured level of60mL/min/1.73m2 for
creatinine levels above the institutional normal. For patients
with gliomas or brain metastases, only those patients receiv-
ing a stable dose of corticosteroids andwhowere seizure-free
for at least 1month before enrollment were eligible. Patients
taking CYP 450 enzyme-inducing anticonvulsant drugs were
switched to other medications at least 7 days before the first
dose of pazopanib. Patients requiring anticoagulation were
required to be on a stabilized dose of low molecular weight
heparin. Therapeutic anticoagulation with warfarin was not
permitted. Patients with biliary obstruction were eligible if
the stent had been in place for at least 10 days before study
initiation and liver function was stable for at least 2 days
without any categorical change in hepatic dysfunction stra-
tum. Radiotherapy was required to be completed 4 weeks or
more before entering the study; chemotherapy, targeted
therapy, or biotherapy for 3weeks ormore; and nitrosoureas
ormitomycinC for 6weeks ormore. Agentswith longer half-
lives (such as suramin and bevacizumab) required longer
elimination periods. Patients were not eligible if they had
received prior therapy with pazopanib, had major surgery
within 28 days before treatment, or were receiving any other
concurrent investigational agents. Pregnant patients and
patients with human immunodeficiency virus, or uncon-
trolled intercurrent illness were also excluded. The following
patients were not eligible for this study: patients with a
serious or nonhealingwound, ulcer, or bone fracture; history
of abdominal fistula, gastrointestinal perforation, or intra-
abdominal abscess within 28 days of treatment; a cerebro-
vascular accident, myocardial infarction, baseline QTc480
msec, recent admission for unstable angina, cardiac angio-
plasty, or stenting within 6 months of entry.
Translational Relevance
Pazopanib is a potent, multitargeted receptor tyrosine
kinase inhibitor approved for the treatment of renal
cancer and soft tissue sarcoma. Clinical activity has also
been observed in urothelial, ovarian, and non–small cell
lung cancer. Because patients with hepatic impairment
are typically excluded from studies conducted during the
clinical development of a new drug, safe dosing guide-
lines are usually not available at the time of approval.
Hepatic dysfunction is common in patients with cancer,
either as a result of comorbid conditions or because of
the cancer itself. The Food and Drug Administration
(FDA) has recognized this as a significant unmet clinical
need, and therefore, they recently began requiring that
safety and pharmacokinetic studies in patients with liver
dysfunction be either completed or planned by the time
of first approval. Therefore, the current study was con-
ducted to describe the pharmacokinetics and determine
the maximum-tolerated dose of pazopanib in patients
with varying degrees of hepatic impairment.
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Drug administration
Pazopanibwas given orally once a day (1 hour before or 2
hours after a meal to minimize the effects of food on
absorption) on days 1 to 21 of a 21-day cycle. For days on
which pharmacokinetic samples were obtained, patients
were instructed to take their daily dose after the pretreat-
ment blood draw to allow accurate timing of subsequent
pharmacokinetic blood draws.
Study design
This was a multi-institutional study conducted at 16
participating sites. Institutional Review Board (IRB)
approval was obtained at each participating site and the
City of Hope Comprehensive Cancer Center was the
coordinating center for this National Cancer Institute
Organ Dysfunction Working Group (NCI-ODWG) study.
Patients were stratified into 4 groups [A (normal), B
(mild), C (moderate), and D (severe)], using the NCI-
ODWG categories of liver dysfunction for trials involving
anticancer therapeutics (Table 1; ref. 8). Both bilirubin
and serum ALT were used to define each group; if the total
bilirubin level and ALT level indicated different groups,
enrollment was into the group with the greatest degree of
liver dysfunction. No distinction was made between liver
dysfunction due to metastases or other causes. All liver
function tests were repeated within 24 hours before the
start of treatment and patients whose degree of hepatic
dysfunction changed between registration and initiation
of protocol therapy were reassigned to a different dys-
function group and dose level after discussion with the
principal investigator. Patients in group A (normal) were
included in this study to obtain concurrent pharmacoki-
netics data in a subject population with normal hepatic
function. Although adverse events (AE) data were
recorded for group A, there were no dose escalations
because the maximum-tolerated dose was defined in
previous studies (7). In the other groups, patients were
evaluable for the purpose of cohort dose escalations if in
the first cycle they either experienced a dose-limiting
toxicity (see below) or received at least 80% of the
planned treatment dose and were followed for one full
cycle without a dose-limiting toxicity. Group B (mild) was
defined according to either of 2 criteria (B1 and B2).
Groups B1 and B2 were combined for dose level alloca-
tion and all analyses. For safety reasons, patients in group
D (severe) were enrolled only after it was possible to
escalate the dose in groups B (mild) and C (moderate).
Because treatment delays would be detrimental for
patients in the eligible population and it was likely that
several patients would not be evaluable for cohort dose-
escalation decisions, the typical 3þ3 up and down dose-
escalation rules were modified to allow accrual of up to 6
patients at a level if less than 3 patients were evaluable and
less than 2 had experienced dose-limiting toxicities. Dose
finding was carried out independently for each of the liver
dysfunction groups; however, the dose recommended for a
group with greater liver dysfunction could not be greater
than that for a groupwith a lesser dysfunction. In eachof the
liver dysfunction groups, 6 patients in an expansion cohort
were treated at the maximum-tolerated dose (or the highest
allowed dose) to obtain more extensive pharmacokinetic
data. Themaximum-tolerated dose was defined as the high-
est dose at which no more than one instance of dose-
limiting toxicity was observed among the first 6 patients
treated.
Dose-limiting toxicities
Toxicity was graded according to the NCI Common
Terminology Criteria for Adverse Events (CTCAE) version
3.0. First-cycle dose-limiting toxicities guided cohort dose
escalations. Dose-limiting toxicities definitions from the
NCI CTEP protocol template were modified for patient
safety and defined as: a required dose reduction before 17
doses (80%) of pazopanib were administered in the first
cycle of treatment; delays in next treatment cycle by
2 weeks due to treatment-related toxicity; grade 4 neu-
tropenia, or occurrence of neutropenic fever with ANC
<1.5  109/L; grade 4 thrombocytopenia; grade 3 nausea
Table 1. NCI ODWG liver function classification and dosing schema









Total bilirubin (>35% direct) ULN B1: ULN >1.5–3 >3 ULN
B2: >1.0–1.5 ULN ULN
ALT ULN B1: >ULN Any Any
B2: Any
Dose Level (mg/day) (mg/day) (mg/day) (mg/day)
Level 1 800 (n ¼ 23) 400 (n ¼ 9) 200 (n ¼ 13) 100 (n ¼ 13)
Level 2 800 (n ¼ 14) 400 (n ¼ 7) 200 (n ¼ 19)
Level 3 800 400
Level 4 800
Abbreviations: ULN, upper limit of normal; ALT, alanine aminotransferase.
Study of Pazopanib in Patients with Hepatic Dysfunction
www.aacrjournals.org Clin Cancer Res; 19(13) July 1, 2013 3633
on July 14, 2020. © 2013 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 7, 2013; DOI: 10.1158/1078-0432.CCR-12-3214 
and vomiting if it occurred despite maximal antiemetic
therapy and if hydration was required for >24 hours;
grade 3 diarrhea despite patient compliance with antidi-
arrheal therapy; grade 3 bleeding/hemorrhage; grade 4
hypertension and grade 4 proteinuria; and all other grade
4 nonhematologic toxicities (if an increase in grade above
baseline), except hypersensitivity. Considering the nature
of the patient populations, the changes in total bilirubin
that constituted a dose-limiting toxicities were specific for
each group. For group B, an increase of total bilirubin to
the level defined for the group D lasting > 1 week was a
dose-limiting toxicity. For patients in group C, a 1.5-fold
increase from baseline total bilirubin to level defined for
group D lasting >1 week was a dose-limiting toxicity.
(Note: 1.5-fold increase from baseline total bilirubin
which did not put a patient into group D did not con-
stitute a dose-limiting toxicity). For patients in group D,
a 1.5-fold increase from baseline without recovery to
<1.2  baseline lasting >2 weeks was a dose-limiting
toxicity.
Pharmacokinetics
During the dose-escalation phase of the protocol (mild,
moderate, and severe cohorts), blood samples for pharma-
cokinetic analysiswere collected over 6 hours during a clinic
visit in week 3. During the expansion phase of the protocol
at the maximum-tolerated dose in each liver dysfunction
cohort, blood samples for pharmacokinetic analysis were
collected over 72 hours starting on day 1 and over 24 hours
during a week-3 clinic visit. Pazopanib and its metabolites
(Supplementary Fig. S1) were measured in plasma using
high-performance liquid chromatography–mass spectrom-
etry (HPLC–MS/MS; ref. 7. The method for pazopanib was
validated over the range 0.1 to 50mg/mL. Samples above the
upper limit of quantitation were diluted with blank plasma
to within the validated range before analysis. The method
for the determination of the pazopanib metabolites
GSK1268992, GSK1268997, and GSK1071306 in plasma
was validated over the range 0.05 to 10 mg/mL. The between
run assay precision (%CV) for pazopanib and all metabo-
liteswas 15%or less.Cmax,TmaxAUC(0–6) and/or AUC(0–24),
and CL/F of pazopanib were calculated, as appropriate for
each patient using noncompartmental methods and sum-
mary statistics were tabulated. A normal liver function
cohort was included for comparison of pharmacokinetic
parameters. In addition, the noncompartmental (trapezoi-
dal rule) AUCs of GSK1071306, GSK1268992, and
GSK1268997 were calculated to compare the exposure of
metabolites as a percentage of the pazopanib exposure in
hepatically impaired patients to the exposure to pazopanib




A total of 98 patients were enrolled in the study, one of
whom was not treated (Table 2). The median age of the
study population was 57 years with a range between 24 and
78. A slightly higher proportion of the patients were male
(54%). Colorectal cancer and liver cancer were the 2 most
common types of primary tumor.
Dose-limiting toxicities
GroupB (mild dysfunction). Ninepatientswere enrolled
at 400 mg of pazopanib once daily. Of the 6 patients
evaluable for dose escalation, one experienced a dose-lim-
iting toxicity and grade 4 increased AST. Including the dose-
escalation and expansion patients, 13 were treated at the
Food and Drug Administration (FDA)-approved dose of
800 mg per day, with one dose-limiting toxicity (grade 5
stomach hemorrhage). One patient was accrued, but with-
drew from the study before treatment.
Group C (moderate dysfunction). Three patients were
enrolled at 200 mg of pazopanib once daily without
experiencing a dose-limiting toxicity. Seven patients were
enrolled at a dose of 400 mg. Of the 4 patients evaluable
for dose escalation, 2 experienced a dose-limiting toxicity,
one patient had a grade 4 AST, and the other patient had
grade 4 AST, grade 4 ALT, and grade 3 hyperbilirubine-
mia. In each case, elevations in AST and ALT decreased in
grade after discontinuation of the pazopanib. The dose
was de-escalated to 200 mg and 3 additional patients
were accrued without a dose-limiting toxicity, establish-
ing the maximum-tolerated dose. One dose-limiting tox-
icity, grade 3 hyperbilirubinemia, was observed in the
expansion cohort of 6 patients. Altogether, 1 of 12
patients experienced a dose-limiting toxicity at the max-
imum-tolerated dose.
Group D (severe dysfunction). At the 100 mg dose level,
1 of 6 evaluable patients experienced a dose-limiting tox-
icity, grade 4 bilirubin. This patient with metastatic colon
cancer initiated therapy with a total bilirubin of 7.4 mg/dL.
After 2 weeks of treatment, the bilirubin increased to
11.5 mg/dL. Despite a metal stent placement, the bilirubin
remained greater than 1.5 times the baseline value. Rela-
tionship to pazopanib could not be excluded and this was
considered a dose-limiting toxicity. However, even after
pazopanib was discontinued, the bilirubin continued to
rise likely due to progressive disease. One of the first 6
evaluable patients experienced a dose-limiting toxicity at
the 200 mg dose level, grade 3 diarrhea. On the basis of the
study design and the maximum-tolerated dose established
in groupC, higher doses were not tested in groupD,making
200 mg per day the recommended dose. Five evaluable
patientswere accrued to the expansion cohortwithout dose-
limiting toxicity.
Toxicity data for all cycles. The most frequently occur-
ring treatment-related adverse event across all groups, dose
levels, and cycles were fatigue, diarrhea, nausea, and
increased AST, events known to be associated with pazo-
panib. Frequently occurring AEs were similar among all
groups and dose levels. Table 3 summarizes grade 3 and 4
toxicities observed on trial across all cycles and Supplemen-
tary Table S1 summarizes the most frequently reported
adverse events (all grades).
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Efficacy
Of98enrolledpatients, therewerenocomplete responses.
Therewere4 (4.1%)partial responses (PR):3 ingroupA, and
1 in group B (all at the 800 mg dose level). The partial
responses were seen in patients with fibrosarcoma, leiomyo-
sarcoma, poorly differentiated germ cell tumor and hepato-
cellular carcinoma with duration of treatment ranging from
7 to 22 cycles. The patients with fibrosarcoma and germ cell
received 7 cycles of chemotherapy before coming off trial for
progressive disease. The patient with hepatocellular carci-
nomareceived16cycles of treatmentbut cameoff trialdue to
the development of an abdominal fistula. The patient with
uterine leiomyosarcoma received 22 cycles of treatment but
required a dose reduction after 19 cycles from 800 mg per
day to 400mg per day due to grade 2 proteinuria. Treatment
was stopped due to progressive disease. At the 800 mg per
day dose, stable disease was seen in 19 patients with the
following diagnosis: colon, fibromyxoid, osteosarcoma,
bronchoalveolar, esophageal, rectal, ovarian, leiomyosar-
coma, hepatocellular, breast, neuroendocrine, and gastric.
The duration of treatment ranged from 3 to 27 cycles. In
summary, percentage of best responses in patients evaluated
for response were 18% PR, 47% stable disease (SD), and
35% progressive disease (PD) in group A; 6% PR, 61% SD,
Table 2. Patient demographics by study group and treatment cohort






dysfunction Severe liver dysfunction
Starting dose of
pazopanib (mg)
800 400 800 200 400 100 200
Number of patients 23 9 14 13 7a 13 19
Median Age (range) 58 (24–78) 56 (51–66) 57 (47–78) 58 (36–76) 65 (52–73) 56 (31–70) 51 (39–78)
Gender (number and %)
Male 10 (43%) 3 (33%) 8 (57%) 4 (31%) 7 (100%) 9 (69%) 12 (63%)
Female 13 (57%) 6 (67%) 6 (43%) 9 (69%) 4 (31%) 7 (37%)
Race (number and %)
White 22 (96%) 7 (78%) 12 (86%) 11 (84%) 2 (29%) 10 (76%) 11 (58%)
Black 1 (4%) 1 (11%) 1 (8%) 1 (14%) 1 (8%) 5 (26%)
Asian 1 (11%) 2 (14%) 1 (8%) 4 (57%) 1 (8%) 2 (11%)




Ethnicity (number and %)
Not Hispanic or Latino 22 (96%) 9 (100%) 13 (93%) 9 (69%) 5 (72%) 13 (100%) 15 (79%)
Hispanic or Latino 1 (7%) 4 (31%) 1 (14%) 4 (21%)
Unknown 1 (4%) 1 (14%)
KPSb Score (number and %)
60 1 (4%) 1 (11%) 2 (14%) 1 (8%) 1 (14%) 3 (23%) 5 (26%)
70–80 9 (39%) 5 (56%) 2 (14%) 6 (46%) 5 (72%) 10 (76%) 13 (68%)
90–100 13 (57%) 3 (33%) 10 (72%) 6 (46%) 1 (14%) 1 (6%)
Baseline abnormalities (AEs; number and %)
Grade 1 95 (63%) 44 (60%) 72 (64%) 106 (67%) 39 (47%) 81 (50%) 133 (65%)
Grade 2 48 (32%) 22 (30%) 32 (28%) 44 (28%) 33 (40%) 57 (35%) 45 (22%)
Grade 3 7 (5%) 7 (9%) 9 (8%) 9 (5%) 11 (13%) 20 (12%) 21 (10%)
Grade 4 1 (1%) 5 (3%) 5 (3%)
Type of primary tumor/hematologic malignancy (n)
Bile duct 1 1 1
Breast 4 1
Colon/rectum 6 2 6 9 3 5 10
Liver 1 2 3 1 2 2 2
Lung 1 1 2
Pancreas 1 2 1 1 1
Other (n ¼ 26)
aOne patient was not treated; there is no weight information for this patient.
bKarnofsky Performance Status.
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and 33% PD in group B; 18% SD and 82% PD in group C;
and 12% SD and 88% PD in group D.
Pharmacokinetics
Steady-state pazopanib pharmacokinetics datawere avail-
able in69patients and the results are summarized inTable4.
In addition, the average concentration versus time plots at
steady-state for each of the groups are depicted in Fig. 1. The
median steady-state Cmax in groups A and B at a dose of 800
mg were 52.0 and 33.5 mg/mL, respectively, whereas the
median AUC(0–24) were 888.2 and 774.2 mg/mL  hour,
respectively. Themedian steady-stateCmax at themaximum-
tolerated dose level in patients in groups C and D (200 mg
once daily) were 22.2 and 9.4 mg/mL, respectively, and the
median AUC(0–24) were 256.8 and 130.6 mg/mL  hour,
respectively. Therefore, at the maximum-tolerated dose
in group C, the median steady-state Cmax was 44% and the
median AUC(0–24) was 39% of the values in the normal
group at full dose. At the maximum-tolerated dose in
group D, the median steady-state Cmax was 18% and the
median AUC(0–24) was 15%, of the values in the group A at
full dose, even lower than in group C patients at the
same dose. The median trough concentration (C(0)) for
patients in groups C and D were 16.2 and 5.7 mg/mL,
respectively. As shown in Fig. 1, pazopanib plasma concen-
trations at steady-state were highly variable in all of the
groups. There were no significant differences in the average
systemic exposures in patients in groups A and B treated at a
dose of 800 mg. Likewise, there were no significant differ-
ences in subjects in groups C and D treated with 200 mg,
Table 3. Grade 3 and 4 adverse events at least possibly related to pazopaniba
Group A Group B Group C Group D
Total
normal mild Moderate severe
Dose of pazopanib (mg) 800 400 800 200 400 100 200
Number of patients (%) 23 (100) 9 (100) 14 (100) 13 (100) 6 (100) 13 (100) 19 (100) 97 (100)
Hematologic
Lymphopenia 1(4) 2 (14) 1 (17) 1 (8) 5 (5)
Neutrophil count decreased 1 (7) 1 (1)
Platelet count decreased 1 (8) 1 (1)
Gastrointestinal disorders
Abdominal Pain 1 (8) 1 (1)
Colitis 1 (7) 1 (1)
Diarrhea 2 (11) 2 (2)
Fistula–Abdomen NOS 1 (7) 1 (1)
Nausea 1 (11) 1 (7) 1 (8) 3 (3)
Vomiting 1 (4) 1 (7) 1 (8) 3 (3)
Coagulation
Partial thromboplastin time 1 (8) 1 (1)
Constitutional
Anorexia 1 (11) 1 (17) 2 (2)
Dyspnea 1 (4) 1 (1)
Fatigue 3 (13) 1 (8) 1 (17) 4 (31) 1 (5) 10 (10)




1 (11) 1 (8) 2 (33) 4 (4)
Alkaline phosphatase
increased
2 (22) 1 (8) 1 (8) 1 (5) 5 (5)
Aspartate aminotransferase
increased
3 (33) 1 (8) 2 (33) 2 (15) 3 (16) 11 (11)
Blood bilirubin increased 1 (11) 4 (31) 1 (17) 2 (15) 2 (11) 10 (10)
Metabolic and other
Hypokalemia 1 (5) 1 (1)
Hyponatremia 1 (11) 2 (15) 3 (3)
Hypophosphatemia 1 (11) 1 (8) 1 (5) 3 (3)
Hyperkalemia 1 (11) 1 (1)
Hypertension 1 (4) 1 (11) 1 (7) 2 (15) 5 (5)
aMaximum grade for all cycles in a given patient.
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although there was a trend toward lower average plasma
levels in group D.
The data for the 3 pazopanib metabolites measured at
steady-state are summarized in Supplementary Tables S2
and S3. Although the median values of each of the meta-
bolites decreased with increasing severity of liver
impairment, the ratios of the AUC(0–6) for each of the
metabolites to the AUC(0–6) for the parent drug showed
no apparent differences across all of the liver function
cohorts.
First-dose pazopanib pharmacokinetics data, which were
obtained in the expansion andnormal cohorts, are available
in 50 patients and the results are summarized in Table 5.
The median first-dose Cmax in groups A and B at a dose of
800mgwere 30.8 and23.8mg/mL, respectively, whereas the
median AUC(0–24) were 563.1 and 462.9 mg/mL  hour,
respectively. The median first-dose Cmax at the maximum-
tolerated dose level in groups C and D (200 mg) were 4.1
and 3.7 mg/mL, respectively, and the median AUC(0–24)
were 42.1 and 56.4 mg/mL  hour, respectively. As in the
case of the steady-state pazopanib pharmacokinetics data,
systemic exposures to pazopanib following a single dose at
the maximum-tolerated dose level in patients in groups C
and D were less than the systemic exposure to pazopanib
after administration of 800 mg once daily in patients in
groups A and B. Univarate analyses of various steady-state
and first-dose pazopanib pharmacokinetics parameters ver-
sus total bilirubin, ALT, and albumin revealed no significant
correlations. Although the AUCs of the metabolites were
lower after the first dose than at steady state, the patterns
across hepatic dysfunction groups and metabolites were
similar to those at steady state (Supplementary Table S4).
Discussion
Pazopanib is a multitargeted tyrosine kinase inhibitor
that is approved for the treatment of advanced renal cell
carcinoma and soft tissue sarcomas. However, treatment of
patients with advanced disease can be challenging due to
impaired liver function from metastasis. Pazopanib’s pack-
age insert has a black box warning due to severe and fatal
hepatotoxicity observed in clinical trials and currently there
is limited information regarding pazopanib in patients
with liver dysfunction. In a phase I study of pazopanib in
patients with advanced hepatocellular carcinoma, the max-
imum-tolerated dose was determined to be 600mg per day.
Evidence of antitumor activity was seen at this dose; how-
ever, the 800mg per day dose was not tolerable due to dose-
limiting toxicities of grade 3 malaise and grade 3 AST/ALT
elevation. Liver abnormalities were seen in amajority of the
patients with hepatocellular carcinoma treated with pazo-
panib. AST elevation was seen in 63% of the patients. ALT
elevation occurred in 41% of patients and hyperbilirubine-
mia in 63%of patients.We therefore conducted this clinical
trial with the primary objective of determining the optimal
dose of pazopanib in cancer patientswith varying degrees of
liver dysfunction as determined by the NCI ODWG classi-
fication system.
Steady-state pazopanib pharmacokinetics data were
available for 69 patients. The median steady-state Cmax and











A 800 18 52.0 (17.1–85.7) 2.8 (1.0–24.2) 29.8 (10.3–750.) 260.5 (92.0–475.9) 888.2 (345.5–1482) 0.9 (0.5–2.3)
B 300c 1 32.9 3.0 17.3 170.5 n/a n/a
400 5 22.7 (14.6–39.8) 3.0 (2.0–4.1) 19.3 (6.8–36.6) 125.1 (78.3–205.8) 467.6 0.9
800 12 33.5 (11.3–104.2) 3.0 (0.5–24.4) 24.0 (8.3–74.6) 176.5 (41.4–518.1) 774.2 (214.7–2034.4) 1.0 (0.4–3.7)
C 200 11 22.2 (4.2–32.9) 2.0 (0.0–4.0) 16.2 (3.1–24.2) 122.2 (21.2–182.9) 256.8 (65.7–487.7) 0.8 (0.4–3.0)
400 3 17.6 (13.0–42.5) 4.0 (3.0–5.9) 16.5 (11.8–28.9) 94.1 (74.7–220.0) n/a n/a
D 100 5 2.3 (0.7–12.6) 4.0 (1.1–6.0) 4.2 (2.3–9.4) 12.8 (3.0–69.1) n/a n/a
200 14 9.4 (2.4–24.3) 3.0 (1.0–8.0) 5.7 (1.5–18.4) 49.2 (9.5–134.5) 130.6 (46.9–473.2) 1.7 (0.4–4.3)
aC(0) is the predose plasma concentration and is equivalent to the trough level following the previous dose.
bCL/F calculated as dose/AUC(0–24) at steady-state for the 24-hour dosing interval.


























Group A - 800 mg (n = 16)
Group B - 800 mg (n = 6)
Group C - 200 mg (n = 7)
Group D - 200 mg (n = 8)
Figure 1. Average steady-state pazopanib plasma concentration versus
time plots measured during the week 3 expansion phase.
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AUC in groups A and B at 800 mg are similar to the
corresponding values previously reported in patients with
cancerwithnormal hepatic function (3). Therefore, patients
with mild liver dysfunction would most likely derive the
same benefit from this dose as patients with no hepatic
impairment. However, the median steady-state Cmax and
AUC(0–24) values after administration of 200mg pazopanib
once daily to patients in group C were approximately 44%
and 39%, respectively, of the corresponding median values
after administration of 800mg/day in patients with normal
hepatic function. Although interpretation of the data across
doses is complicated by the fact that the pharmacokinetics
of oral pazopanib are not linear in patients with normal
hepatic function, the plasma concentrations at the maxi-
mum-tolerated dose in group C are clearly lower than the
concentrations at the maximum-tolerated dose in groups A
and B. Administration of 200-mg pazopanib once daily to
patients in group D resulted in median steady-state Cmax
and AUC(0–24) values of only 18% and 15%, respectively,
compared with the 800 mg daily dose in patients with no
liver dysfunction. While the median trough concentration
for patients in group C was within the range of plasma
concentrations associated with clinical and biologic effects
consistent with VEGFR inhibition of 15 to 20 mg/mL in
patients with renal cell carcinoma (3), the median trough
levels in group D was less than the desired level. These data
suggest that the systemic exposure of pazopanib in group D
at the highest dose tested (200 mg/day) may not provide a
therapeutic benefit to these patients.
Pazopanib has been reported to exhibit nonlinear phar-
macokinetics behavior, such that steady-state plasma levels
increase in a less than dose-proportionalmanner (3, 4). As a
result, the mean plasma AUC plateaus at doses above 800
mg. The most likely explanation for pazopanib’s nonlinear
pharmacokinetics behavior is saturable oral absorption.
Interestingly, recent studies have shown that by either
taking pazopanib with food (9) or crushing the tablet
(10), one can increase the oral bioavailability by as much
as 2-fold. On the current trial, patients were instructed to
take pazopanib on an empty stomach in accordance with
the current FDA recommendations and to minimize the
variable effect of food. In contrast to previously published
pharmacokinetics in patients with normal liver biochem-
istry and mildly impaired liver function, our results from
patients with severe hepatic impairment showa greater than
dose-proportional increase in AUC. There were no differ-
ences between the groups with respect to the metabolite to
pazopanib ratios, suggesting that hepatic metabolism of
pazopanib was not affected by the severity of liver dys-
function. There are limited published data at a dose of
200 mg from the initial dose finding studies. Previous
steady-state pharmacokinetics results in patients with
normal or Child-Pugh A liver function receiving 200 mg
show trough levels of 12.4 and 15.4 mg/mL, respectively
(3, 4). The average steady-state trough pazopanib con-
centration from the current study in subjects with severe
hepatic dysfunction treated with 200 mg was 5.7 mg/mL,
suggesting reduced oral absorption. The pharmacokinet-
ics results following a single dose of pazopanib were
consistent with the steady-state data.
Conducting a liver dysfunction clinical trial with a hep-
atotoxic drug can be challenging, but the information
obtained from our study is critical for the management of
many patients. The primary indication for pazopanib is for
patients with advanced renal cell carcinoma. Since many of
these patients may have had nephrectomies, there is con-
cern for potential hepatorenal syndrome. In our study, 98
patients were treated and 7 patients had elevated creatinine
(3—grade 1; 1—grade 2; 2—grade 3; and 1—grade 4). In
our assessment, the grade 3 and 4 creatinine elevations were
not related to treatment, but to disease progression.Overall,
the pharmacokinetics data suggest that the lower maxi-
mum-tolerated dose in patients with moderate or severe
liver dysfunction, comparedwith thosewithnoormild liver
dysfunction is not due to a decrease in drug clearance or an
alteration in the metabolic pattern of pazopanib. Multiple
factors are likely to have contributed to the poorer outcome
for patients in the moderate and severe liver impairment
groups. Concurrent with their hepatic dysfunction, the
patients may have had more extensive disease when they
entered the study. Therefore, they may have been less likely
to have an objective response or stable disease even if they
had tolerated the same drug exposure. It is not surprising
that patients with baseline hepatic dysfunction did not
Table 5. First-dose pazopanib pharmacokinetics in expanded cohorts and the maximum-tolerated dose
(medians and ranges)





A 800 20 30.8 (4.2–66.2) 4.0 (1.0–24.0) 120.6 (10.8–271.3) 563.1 (74.4–1107)
B 200 1 9.4 6.5 41.8 179.8
400 1 13.6 2.0 62.0 223.1
800 6 23.8 (6.1–127.5) 4.6 (2.0–8.3) 103.0 (11.2–403.3) 462.9 (102.0–2147)
C 200 7 4.1 (0.4–13.5) 2.0 (2.0–3.1) 19.7 (1.6–67.1) 42.1 (6.1–231.2)
D 100 3 2.9 (1.8–3.1) 3.0 (2.0–24.2) 13.1 (0.5–13.3) 33.6 (19.5–43.4)
200 12 3.7 (0.5–13.1) 3.5 (2.0–8.3) 17.2 (1.8–57.3) 56.4 (6.3–208.4)
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tolerate a hepatotoxic agent well, leading to overall lower
exposure to the drug and reducing further the likelihood of
clinical benefit. Patients with mild hepatic dysfunction, as
evidenced by total bilirubin in the range of 1.0 to 1.5 times
the ULN or an ALT above the ULN, tolerated full-dose
pazopanib, and should be considered for therapy with this
agent if otherwise appropriate. Patients with moderate or
severe hepatic dysfunction tolerated a 200 mg daily dose.
Furthermore, our pharmacokinetic data do not support the
use of dose individualization for patients with impaired
liver function. This study was not designed, and does not
have the statistical power, to determine whether or not this
reduced dose is efficacious. However, based on the low drug
exposure in patients with severe hepatic dysfunction, both
the FDA package insert and the European Commission
Summary of Product Characteristics do not recommend
pazopanib for patients with severe hepatic dysfunction.
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